Overall, these data show that TLR3 agonist poly(I:C) results in enhancement in numbers and activation of myeloid cells, specifically macrophages and migratory dendritic cells in in the tumor and tumor-draining lymph nodes suggesting that there is an enhanced potential for antigen presentation and formation of an effective immune response. The gene discussed is TLR3; the disease is neoplasm.